Importance: Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury. Observations: We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban. Both were symptomatic, had massively elevated transaminase activity levels and hyperbilirubinemia, and fulfilled the criteria of Hy’s law.

READ FULL ARTICLE Curated publisher From Jamanetwork